Navigation Links
Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
Date:9/16/2011

tudy for the treatment of adenovirus infection in pediatric and adult hematopoietic cell transplant patients (AdV HALT Trial/CMX001-202); and an Open-Label Study (CMX001-350) for the treatment of dsDNA viral infections.  

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  Based on proprietary lipid conjugate technology, the company's two clinical stage compounds have demonstrated enhanced activity, bioavailability and safety compared to currently approved drugs.  CMX001 is a lipid-antiviral-conjugate that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate.  Its broad spectrum activity against double-stranded DNA (dsDNA) viruses without the myelotoxicity and nephrotoxicity of current agents has the potential to improve outcomes for immunosuppressed patients.  Chimerix's second clinical-stage antiviral compound, CMX157 is a lipid-antiviral-conjugate that delivers high intracellular levels of the active antiviral agent tenofovir-diphosphate.  It has the potential to directly address several limitations of current HIV and HBV therapies.  Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, influenza, malaria and other global public health needs.  For additional information on Chimerix, please visit http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 IRIDEX Corporation (Nasdaq: IRIX ... six months ended June 28, 2014.  , Revenues ... 15% from $9.2 million in the 2013 second quarter and ... 2014. Revenues for the first six months of 2014 were ... six months of last year. , Gross margin for ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
(Date:7/31/2014)... July 31, 2014 Nektar Therapeutics (Nasdaq: ... quarter ended June 30, 2014. Cash and ... million as compared to $309.1 million at March 31, 2014."The ... Nektar as we look forward to significant milestones for a ... President and Chief Executive Officer of Nektar. "The first of ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... and work in manufacturing jobs may have significantly less endurance than ... study of 32 people -- half were obese, half were of ... that were about 60 percent longer. Obesity also was associated ... Being older -- 50 to 65 years of age ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Almost 140 people ... transportation in the United States. But there ... catastrophes, Dawne Gardner, injury prevention coordinator at Cincinnati ... said in a medical center news release. ... to school, it,s important for parents and children ...
(Date:8/1/2014)... Summer is here, and with it comes ... summer, and they can be a pain for dogs. Animal ... all their customers get rid of ticks and prevent them ... in the summer, which is why they are so active ... and woodland areas and carry a number of diseases, including ...
(Date:8/1/2014)... 1, 2014Lesbian, gay, bisexual, and transgender individuals who want ... as some of their heterosexual and cisgendered peers, such ... additional physiological and legal challenges to become parents. ... assisted reproduction options is presented in the article " ... published in LGBT Health , a ...
(Date:8/1/2014)... 01, 2014 Growing prevalence of ... healthcare reforms are boosting healthcare market growth, although ... discounts and increasing generic consumption is a major ... million in 2013, having grown at a Compound ... The implementation of the Health Transformation Program (Saglikta ...
Breaking Medicine News(10 mins):Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4
... molecule called RBP4 (retinol binding protein 4) is an indication ... insulin resistance //, the main cause of type 2 ... a recent study. ,Researchers at Beth Israel Deaconess ... target, and also offers an early method of identifying individuals ...
... suspected connection between MMR(measles, mumps and rubella) vaccine and bowel ... of the vaccine, despite the assurances extended by government ... is to be initiated by the Department of Health, and ... were affected by the vaccine. The offer comes after a ...
... the globe die every year of environmental-linked diseases, ... ,The four main diseases influenced by poor ... various forms of unintentional injuries and malaria, said ... through Healthy Environments", underlined that over 40 percent ...
... of HIV positive patients in Bihar, a high profile ... state legislature and those connected// with AIDS awareness programme ... a more forceful drive against the dreaded disease, official ... inaugurate the day-long brainstorming session on June 24 here, ...
... their lives the older they get, with the greatest level of ... study//. ,Researchers at the VA Ann Arbor Healthcare System ... - the first group between 21 and 40 years age, and ... researchers asked the participants to rank their own happiness on a ...
... fatigue, bodily changes and stress all links with psychological approach ... the recent issue of Perspectives// on Psychological Science elaborates. ... to view hills as steeper when we are tired, less ... greater and the distance to the ground appears further when ...
Cached Medicine News:Health News:A New Marker For Type-2 Diabetes ? 2Health News:13 million environment-linked deaths every year: WHO 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
Medicine Products: